Search Clinical Trials
Below please find a list of studies actively recruiting volunteers at one of the following GHUCCTS institutions: Georgetown University, Howard University, MedStar Health Research Institute, or Washington DC VA Medical Center. Please enter your search criteria below to help find a study for you. If you have any questions, please email us or call us at 301-560-2963.
Sponsor Condition of Interest |
---|
Peer-Led Diet and Exercise Intervention
VA Office of Research and Development
Physical Activity
Peer Leaders
Diet Quality
The majority of older Veterans do not meet the minimum healthy diet or physical activity
recommendations, despite known benefits. Identifying novel ways to increase adherence to
rehabilitation programs that improve dietary quality and physical activity may reduce the
risk of disability in older Veterans.... expand
The majority of older Veterans do not meet the minimum healthy diet or physical activity recommendations, despite known benefits. Identifying novel ways to increase adherence to rehabilitation programs that improve dietary quality and physical activity may reduce the risk of disability in older Veterans. Peer-based interventions may be one method to facilitate lasting behavioral change since peers often share a common culture and knowledge about the problems that their community experiences. The investigators propose to develop and evaluate a novel peer-led diet and exercise intervention that targets older Veterans with multiple chronic health conditions. Successful development and pilot of this intervention will provide the preliminary data for a larger multisite trial focused on the use of peer-led interventions to improve long-term compliance to lifestyle interventions in older Veterans. Type: Interventional Start Date: Aug 2023 |
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension...
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver
fibrosis histological stage F2 or F3 expand
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3 Type: Interventional Start Date: Aug 2021 |
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple...
Hackensack Meridian Health
Multiple Myeloma
This is a prospective, 2-arm (with an additional exploratory arm), open-label,
multicenter study looking at the response rate of patients receiving selinexor (KPT-330),
in combination with carfilzomib, daratumumab or pomalidomide.
Multiple Myeloma patients with documented disease progression or... expand
This is a prospective, 2-arm (with an additional exploratory arm), open-label, multicenter study looking at the response rate of patients receiving selinexor (KPT-330), in combination with carfilzomib, daratumumab or pomalidomide. Multiple Myeloma patients with documented disease progression or refractory disease while on current treatment with any carfilzomib-containing regimen (arm 1), any pomalidomide-containing regimen (arm 2) or any daratumumab-containing regimen (exploratory arm) will be included in the study. Patients will be assigned to the respective groups according to their current treatment. If a subject has received more than one of the above therapies, then assignment will be made at their physician's discretion (e.g treatment decision can be made based upon patient and physician preferred tolerance.). Patients will receive treatment until progressive disease (PD), death, toxicity that cannot be managed by standard of care, or withdrawal, whichever occurs first. Type: Interventional Start Date: Mar 2021 |
Fecal Microbiota Transplant National Registry
American Gastroenterological Association
Fecal Microbiota Transplantation
Clostridium Difficile Infection
Gut Microbiome
A national data registry of patients receiving fecal microbiota transplantation (FMT) or
other gut-related-microbiota products designed to prospectively assess short and
long-term safety and effectiveness expand
A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness Type: Observational [Patient Registry] Start Date: Sep 2017 |
HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections...
Inflammatix
Respiratory Tract Infections
Urinary Tract Infections
Intra-Abdominal Infections
Skin and Soft Tissue Infection
Suspected Meningitis/Encephalitis or Any Other Infection
This study will analyze gene expression and other laboratory data from biological samples
collected from participants with suspected respiratory, urinary, intra-abdominal, and/or
skin & soft tissue infections; or suspected sepsis of any cause. expand
This study will analyze gene expression and other laboratory data from biological samples collected from participants with suspected respiratory, urinary, intra-abdominal, and/or skin & soft tissue infections; or suspected sepsis of any cause. Type: Observational Start Date: Feb 2020 |
Evaluating Novel Therapies in ctDNA Positive GI Cancers
Georgetown University
Colon Adenocarcinoma
Rectal Adenocarcinoma
Gastric Adenocarcinoma
Pancreatic Adenocarcinoma
Hepatocellular Carcinoma
This study is a non-randomized, open-label, multi-cohort, multi-site, pilot feasibility
therapeutic trial. The study will enroll 20 patients across 4 cohorts (CRC, gastric,
PDAC, and HCC/intra-hepatic-/extra-hepatic-, gall bladder adenocarcinomas) diagnosed with
histologically confirmed GI cancers.... expand
This study is a non-randomized, open-label, multi-cohort, multi-site, pilot feasibility therapeutic trial. The study will enroll 20 patients across 4 cohorts (CRC, gastric, PDAC, and HCC/intra-hepatic-/extra-hepatic-, gall bladder adenocarcinomas) diagnosed with histologically confirmed GI cancers. These patients will have already completed all Standard of Care (SOC) treatments (including neoadjuvant, surgery, local therapies, and/or adjuvant therapy as applicable), as defined by the treating primary physician or research team, with curative intent but have a positive SignateraTM tumor-informed ctDNA test and NED radiographically by standard imaging within 28 days prior to enrollment and within 1 year of completing all curative-intent therapy. All patients will be treated with intravenous (IV) atezolizumab 1200 mg IV and bevacizumab 15 mg/kg on Day 1 of 21-day cycles until disease recurrence, ctDNA POD, unacceptable toxicity, or subject withdrawal of consent with a maximum 12 month total duration of study therapy. Atezolizumab and bevacizumab drug will be provided. Type: Interventional Start Date: Mar 2023 |
Development of a City-Wide Cohort of HIV-Infected Persons in Care in the District of Columbia: The DC...
George Washington University
HIV
AIDS
The goal of the DC Cohort is to establish a clinic-based city-wide longitudinal cohort
that will describe clinical outcomes, and improve the quality of care for outpatients
with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) in
Washington, DC. expand
The goal of the DC Cohort is to establish a clinic-based city-wide longitudinal cohort that will describe clinical outcomes, and improve the quality of care for outpatients with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) in Washington, DC. Type: Observational Start Date: Jan 2011 |
Transvaginal Low-level Laser Therapy to Improve Pelvic Pain and Sexual Function in Patients With Endometriosis.
Medstar Health Research Institute
Endometriosis
Dyspareunia
Pelvic Pain
Dyspareunia is defined as pain with penetrative sexual intercourse. Women with
endometriosis have a nine-fold increased risk of dyspareunia, when compared to the
general female population.
A prospective single-blinded randomized controlled trial will be performed evaluating the
change in pelvic... expand
Dyspareunia is defined as pain with penetrative sexual intercourse. Women with endometriosis have a nine-fold increased risk of dyspareunia, when compared to the general female population. A prospective single-blinded randomized controlled trial will be performed evaluating the change in pelvic pain and sexual satisfaction scores from baseline to 6 weeks after treatment with transvaginal photobiomodulation therapy or sham therapy. Treatment will involve 9 planned treatment sessions over 3-4 weeks. 40 women will be included in the study. Type: Interventional Start Date: May 2023 |
Ketorolac vs Oxycodone for Great Toe Arthrodesis
Medstar Health Research Institute
Arthrodesis
This study reviews if taking ketorolac, after a joint fusion procedure, can decrease the
need for taking oxycodone (standard of care) for pain relief. The study also investigates
if ketorolac affects bone healing after surgery. expand
This study reviews if taking ketorolac, after a joint fusion procedure, can decrease the need for taking oxycodone (standard of care) for pain relief. The study also investigates if ketorolac affects bone healing after surgery. Type: Interventional Start Date: Apr 2020 |
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous...
Melanoma and Skin Cancer Trials Limited
Cutaneous Melanoma, Stage II
Patients with a primary invasive melanoma are recommended to undergo excision of the
primary lesion with a wide margin. There is evidence that less radical margins of
excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm
margin of excision of the primary lesion for... expand
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of life. Type: Interventional Start Date: Dec 2019 |
Transcatheter Aortic Prosthesis Function: A Long-term Follow-up Study
Medstar Health Research Institute
Aortic Valve Replacement
In this observational study, the investigators will enroll subjects who underwent TAVR or
SAVR more than 3 years ago. Clinical and procedural data from the implant/surgery will be
collected, alongside clinical and echocardiographic data from subsequent follow-up
visits. expand
In this observational study, the investigators will enroll subjects who underwent TAVR or SAVR more than 3 years ago. Clinical and procedural data from the implant/surgery will be collected, alongside clinical and echocardiographic data from subsequent follow-up visits. Type: Observational Start Date: Feb 2018 |
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
Exact Sciences Corporation
Colorectal Cancer
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete
surgical resection for stage II or III colorectal cancer. Patients will be followed for a
minimum of 3 years and up to 5 years for recurrence. expand
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence. Type: Observational Start Date: Dec 2021 |
Quality of Life in Patients With Clinically Localized Prostate Cancer Treated With Radiosurgery
Georgetown University
Prostate Cancer
Localized Malignant Neoplasm
Quality of life data following SBRT for prostate cancer has been obtained in only a small
numbers of patients. A prospective study using validated quality of life questionnaires
is needed to determine outcomes after treatment with SBRT. Our study will be the first
essential step in developing a better... expand
Quality of life data following SBRT for prostate cancer has been obtained in only a small numbers of patients. A prospective study using validated quality of life questionnaires is needed to determine outcomes after treatment with SBRT. Our study will be the first essential step in developing a better evidence base on the comparative risks and benefits of SBRT treatment with regards to quality of life assessment and outcomes. Type: Observational Start Date: Dec 2012 |
2-level Cervical Disc Replacement Comparing Prodisc C SK & Vivo to Mobi-C
Centinel Spine
Symptomatic Cervical Disc Disease
A multi-center, prospective, randomized, controlled comparison of the prodisc C SK and
prodisc C Vivo to the control, a similar, legally marketed total disc replacement device
in subjects with symptomatic cervical disc disease (SCDD). expand
A multi-center, prospective, randomized, controlled comparison of the prodisc C SK and prodisc C Vivo to the control, a similar, legally marketed total disc replacement device in subjects with symptomatic cervical disc disease (SCDD). Type: Interventional Start Date: Aug 2019 |
DC Longitudinal Study on Aging and Specimen Bank
Georgetown University
Alzheimer Disease
Dementia
Mild Cognitive Impairment
Aging
Aging Disorder
The Georgetown University Memory Disorders Program, part of the Department of Neurology,
is conducting pilot studies of the feasibility of various diagnostic tests for
Alzheimer's disease, mild cognitive impairment and other neurodegenerative diseases.
Further, this study is assessing longitudinal... expand
The Georgetown University Memory Disorders Program, part of the Department of Neurology, is conducting pilot studies of the feasibility of various diagnostic tests for Alzheimer's disease, mild cognitive impairment and other neurodegenerative diseases. Further, this study is assessing longitudinal changes in biological, lifestyle, and cognitive assessment collection. The primary goal of this study is to examine the feasibility of biochemical assays, genetic testing, and cognitive and lifestyle assessments in the ante-mortem diagnosis of Alzheimer's disease, mild cognitive impairment and other neurodegenerative diseases. This research involves genetic and cognitive status testing but the findings will not be shared with research subjects. This will be accomplished ex vivo using blood, and/or cerebrospinal fluid (CSF) specimens from patients with a diagnosis of probable Alzheimer's disease, mild cognitive impairment, or other neurodegenerative diseases and from normal controls. Type: Observational Start Date: Jan 2007 |
CLEANer Aspiration for Pulmonary Embolism
Argon Medical Devices
Pulmonary Embolism
Acute Pulmonary Embolism
Cardiovascular Diseases
Venous Thromboembolism
To evaluate the safety and efficacy of the Cleanerâ„¢ Pro Thrombectomy System for
aspiration thrombectomy in patients with acute pulmonary embolism (PE). expand
To evaluate the safety and efficacy of the Cleanerâ„¢ Pro Thrombectomy System for aspiration thrombectomy in patients with acute pulmonary embolism (PE). Type: Interventional Start Date: Oct 2024 |
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive...
Sanofi
Multiple Sclerosis
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is
to determine the efficacy of frexalimab in delaying the disability progression and the
safety up to approximately 51 months administration of study intervention compared to
placebo in male and female participants... expand
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: - This event-driven study will have variable duration ranging from approximately 27 to 51 months. - The study intervention duration will vary ranging from approximately 12 to 51 months. - The number of scheduled visits will be up to 27 (including 3 follow-up visits) with a visit frequency of every month for the first 6 months and then every 3 months. Type: Interventional Start Date: Dec 2023 |
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Merck Sharp & Dohme LLC
Endometrial Cancer
Researchers are looking for new ways to treat people with endometrial cancer (EC) who
have previously received treatment with platinum based therapy (a type of chemotherapy)
and immunotherapy. Immunotherapy is a treatment that helps the immune system fight
cancer. This clinical study will compare... expand
Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical study will compare MK-2870 sacituzumab tirumotecan to chemotherapy. The goal of the study is to learn if people who receive MK-2870 sacituzumab tirumotecan live longer overall and without the cancer getting worse compared to people who receive chemotherapy. Type: Interventional Start Date: Dec 2023 |
MAGNITUDE: a Phase 3 Study of NTLA-2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy...
Intellia Therapeutics
Transthyretin Amyloidosis (ATTR) with Cardiomyopathy
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in
participants with ATTR-CM. expand
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM. Type: Interventional Start Date: Dec 2023 |
Shockwave C2+ 2Hz Coronary IVL Catheter in Calcified Coronary Arteries (Disrupt CAD DUO)
Shockwave Medical, Inc.
Coronary Artery Disease
Myocardial Infarction
This investigational device exemption (IDE) study is to assess the safety and
effectiveness of the Shockwave Coronary Intravascular Lithotripsy (IVL) System with the
Shockwave C2+ 2Hz Coronary IVL Catheter to treat de novo, calcified, stenotic, coronary
lesions prior to stenting. expand
This investigational device exemption (IDE) study is to assess the safety and effectiveness of the Shockwave Coronary Intravascular Lithotripsy (IVL) System with the Shockwave C2+ 2Hz Coronary IVL Catheter to treat de novo, calcified, stenotic, coronary lesions prior to stenting. Type: Interventional Start Date: Dec 2023 |
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
NRG Oncology
Breast Cancer
Cognitive Impairments
This Phase III trial will examine the efficacy of computerized cognitive training methods
on perceived cognitive impairment in breast cancer survivors. expand
This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors. Type: Interventional Start Date: Apr 2024 |
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack-...
Janssen Research & Development, LLC
Ischemic Stroke; Ischemic Attack, Transient
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the
risk of recurrent ischemic stroke. expand
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke. Type: Interventional Start Date: Feb 2023 |
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease...
University of Minnesota
COVID-19
Treatments are needed to improve outcomes among patients hospitalized for COVID-19,
including direct-acting antiviral (DAA) agents to mitigate the pathology driven by
ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an
anti-SARS-CoV2 3C-like protease inhibitor (PI) developed... expand
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi &; Co. Ltd. The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of ensitrelvir when given in addition to standard of care (SOC) for inpatients with COVID-19. The SOC will be determined by local established guidelines and may include additional DAA (e.g., remdesivir) and immunomodulatory treatment strategies. Certain SOC treatments will be pre-specified prior to randomization. Type: Interventional Start Date: Dec 2022 |
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and...
Janssen Research & Development, LLC
Relapsed or Refractory Multiple Myeloma
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC)
in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in
combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination
with pomalidomide and dexamethasone... expand
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd). Type: Interventional Start Date: Oct 2022 |
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and...
Theratechnologies
HIV Infections
Multi-Antiviral Resistance
The virological efficacy of ibalizumab has been clearly demonstrated in multiple clinical
trials. This study will expand ibalizumab's clinical data set and allow a better
understanding of the virologic response durability on ARV regimens with or without
ibalizumab in a heterogeneous real-world patient... expand
The virological efficacy of ibalizumab has been clearly demonstrated in multiple clinical trials. This study will expand ibalizumab's clinical data set and allow a better understanding of the virologic response durability on ARV regimens with or without ibalizumab in a heterogeneous real-world patient population. Additional data on the efficacy and safety of ibalizumab and its impact on patient reported outcomes will be captured until study end. Primary Objective: To evaluate the long-term efficacy, safety, and durability of ibalizumab in combination with other ARVs by comparing the virologic, immunologic and clinical outcomes of patients receiving ibalizumab treatment versus patients not receiving ibalizumab. Secondary Objective: To assess the efficacy of ibalizumab in combination with other antiretrovirals by comparing the virologic, immunologic, clinical and patient reported outcomes of patients before and after they receive ibalizumab treatment. To assess the long-term safety and tolerability of ibalizumab. Other Objectives: To assess risk factors/predictors of virologic and immunologic response. To assess efficacy and safety in special populations that enroll. Type: Observational Start Date: Mar 2022 |
- Previous
- Next